From Jar to Hospital: How Honey Becomes an FDA-Cleared Dressing
A jar of honey is not a medical product. Dr. Ferhat Öztürk's research asks what makes honey medical-grade — and the FDA's answer runs through the 510(k) pathway, product code FRO, and a line of MEDIHONEY precedents. The regulatory road from hive to hospital.
Dr. Ferhat Öztürk spends his research life asking what makes honey medical-grade. But a jar of honey — however antibacterial in the lab — is not a medical product. The road from jar to hospital runs through a regulatory address: in the United States, honey-based wound dressings are regulated as medical devices, cleared through the FDA's 510(k) pathway under product code FRO (“Dressing, wound, drug”). This is an educational tour of that road — the precedents, the standards, and the discipline the category demands.
The regulatory address: 510(k), product code FRO
A 510(k) clearance is not an approval of a new idea from scratch; it is a demonstration of substantial equivalence to an already-cleared predicate device. For honey wound dressings, that predicate chain has a flagship name: MEDIHONEY, developed by Derma Sciences (later Integra LifeSciences). The first FDA clearance for a MEDIHONEY line dates to about 2007, and the chain has been extended line by line ever since — a January 2025 review in Advanced Therapeutics (“Bee better”) counted more than twenty FDA-cleared honey-based wound products.
| Clearance | Product | Cleared |
|---|---|---|
| K072956 | MEDIHONEY Primary Wound Dressings | Early predicate clearance |
| K080315 | MEDIHONEY Wound & Burn Dressing | Early predicate clearance |
| K110546 | MEDIHONEY Hydrogel Sheet Dressings with Active Leptospermum Honey | July 27, 2011 |
| K133279 | MEDIHONEY calcium alginate wound dressings | June 25, 2015 |
The later clearances show how the category matured. K110546 (2011) covered a hydrogel sheet dressing; K133279 (2015) covered a calcium alginate variant with indications including diabetic foot ulcers, leg ulcers, pressure ulcers, first- and second-degree burns, donor sites, and traumatic and surgical wounds. Each clearance leaned on the ones before it — the predicate chain doing exactly what the 510(k) system was designed for.
What makes honey “medical-grade”
Regulatory clearance is only half the story; the other half is the standard the substance itself must meet. The 2025 Journal of Wound Care consensus paper co-authored by Öztürk — “Medical-grade honey: its definition and refined standards” (DOI: 10.12968/jowc.2024.0206) — defines the term: organic production, gamma sterilization (per ISO 11137) that preserves bioactivity, documented clinical safety benchmarks, and physicochemical criteria. In short: measured antibacterial activity, not just sweetness.
Checklist
What the category's history shows matters
- A predicate strategy: cleared predicates such as the MEDIHONEY line anchor substantial-equivalence arguments.
- Sterility assurance: gamma sterilization per ISO 11137, without destroying the bioactivity that justifies the product.
- Packaging integrity: the 2025 Class II recalls of MediHoney gel and hydrogel sheet dressings centered on packaging and sterile-barrier defects — manufacturing quality is clinical quality.
- Measured criteria: antibacterial activity documented lot by lot, not claimed on the label.
The discipline lesson is recent. In 2025 the FDA logged Class II recalls of MediHoney gel (initiated January 10, 2025, over an induction-seal and packaging defect) and MediHoney hydrogel sheet dressings (initiated August 5, 2025, over packaging failures risking a sterile-barrier breach), with Integra LifeSciences as manufacturer of record. Meanwhile the 2025 consensus paper notes that the EU's Medical Device Regulation is raising the evidence bar for natural-product devices. The category is growing up — and the bar moves with it.
The market-access lens
Vendor research firms estimate the medical-grade honey dressings market at roughly $135M in 2025, growing toward about $220M by 2032 (estimates vary by vendor) — a market small enough that channel quality and clinical champions decide the winners. That is where Öztürk's research program sits in the pipeline: generating the measured evidence — bioactivity screening, standards definitions — on which predicate chains, dossiers, distributor conversations, and hospital pilots all depend.
ghmap.io covers the field's agenda: companies, products, regulation, and market access. The jar-to-hospital journey is the innovation pipeline in miniature — evidence, standard, clearance, channel, payment — and every stage has its own calendar, documents, and gatekeepers. Science opens the door; market access walks through it, country by country.
Frequently asked questions
Q: How are honey wound dressings regulated in the United States?
A: As medical devices, cleared through the FDA's 510(k) pathway under product code FRO (“Dressing, wound, drug”) — by demonstrating substantial equivalence to a cleared predicate device.
Q: What are the key FDA precedents?
A: The MEDIHONEY line (Derma Sciences, later Integra LifeSciences): early clearances K072956 and K080315, the hydrogel sheet dressing K110546 (cleared July 27, 2011), and the calcium alginate variant K133279 (cleared June 25, 2015).
Q: What does “medical-grade” honey actually mean?
A: Per the 2025 Journal of Wound Care consensus paper co-authored by Öztürk: organic production, gamma sterilization, documented clinical safety benchmarks, and physicochemical criteria — measured antibacterial activity, not just sweetness.
Q: Have honey wound products faced recalls?
A: Yes. In 2025 the FDA logged Class II recalls of MediHoney gel and hydrogel sheet dressings over packaging and sterile-barrier defects — a reminder that manufacturing quality is clinical quality.
Q: How large is the market?
A: Vendor research estimates put medical-grade honey dressings at roughly $135M in 2025, growing toward about $220M by 2032 — but estimates vary by vendor, so treat figures as directional.
If you are bringing a wound-care or natural-product innovation toward a first market — first clearance, first distributor, first hospital pilot — a ghmap.io market-entry brief maps your stages. See the link below.
Next step
Bringing a wound-care or natural-product innovation toward a first market? A ghmap.io market-entry brief maps your stages — pathway, documentation, channel, and payment. Planning conversations, not approval services and not outcome guarantees.
Get a market-entry brief
